SOXL finally letting me buy some shares back.
Gaeilge said:
Closed my META short. I'll take 22pts and call it good.
Ragoo said:
In the endurance world NIKE shoes are a tier below.
On
Hoka
Asics
Are probably the top 3 brands.
not in TriathlonThe Pilot said:Ragoo said:
In the endurance world NIKE shoes are a tier below.
On
Hoka
Asics
Are probably the top 3 brands.
It's been a couple of years since I've done a marathon, but I think I'd still put Nike above On and Asics. Hoka's are pretty popular with more casual runners. Seems like the elites still are mostly Nike Alphafly's.
The Pilot said:Ragoo said:
In the endurance world NIKE shoes are a tier below.
On
Hoka
Asics
Are probably the top 3 brands.
It's been a couple of years since I've done a marathon, but I think I'd still put Nike above On and Asics. Hoka's are pretty popular with more casual runners. Seems like the elites still are mostly Nike Alphafly's.
Brian Earl Spilner said:
KORU is looking interesting again.
Started nibbling again today. Had sold out at $20.
Brian Earl Spilner said:
SOXL finally letting me buy some shares back.

El Chupacabra said:
Anyone retiring early on MRNA news? (Up 100% pre market)
Hill08 said:Brian Earl Spilner said:
KORU is looking interesting again.
Started nibbling again today. Had sold out at $20.
Not a lot of momo for the morning. Market looks negative in the AM. Semis don't have much in the coming days. Did increase MRVL today.
Quote:
Why Do We Think Moderna Will Underperform?
We're glad investors have benefited from the price increase, but we don't have much confidence in Moderna. Here are three reasons why MRNA doesn't excite us, plus one stock we'd rather own.
1. Revenue Spiraling Downwards
Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Moderna's demand was weak over the last five years as its sales fell at a 20.5% annual rate. This was below our standards and signals it's a low quality business.
2. EPS Trending Down
Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable for example, revenue could be inflated through excessive spending on advertising and promotions.
Sadly for Moderna, its EPS declined by 24.5% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.
3. Free Cash Flow Margin Dropping
If you've followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can't use accounting profits to pay the bills.
As you can see below, Moderna's margin dropped by 95.9 percentage points over the last five years. It may have ticked higher more recently, but shareholders are likely hoping for its margin to at least revert to its historical level. Almost any movement in the wrong direction is undesirable because of its already low cash conversion. If the longer-term trend returns, it could signal it's in the middle of a big investment cycle. Moderna's free cash flow margin for the trailing 12 months was negative 55.8%.
Brian Earl Spilner said:
Brother, I haven't traded SOXS in several years.
flashplayer said:
Treasury announcement responsible for this morning's mini pop:
https://breakingthenews.net/Article/US-Treasury-increases-buyback-operation-sizes/66949448
Has put a dent in treasury yields so far. I'm not wise enough to understand exactly what this means as far as ramifications.
They might know something ✍
— Trade With Congress (@tradewithcong) August 19, 2026
As of right now, 4 different politicians have bought the dip on $ZTS Zoetis
- Gil Cisneros
- Ro Khanna
- Chuck Fleishman
- Byron Donalds
Why?
Zoetis is the pet pharmaceutical company that developed Librela, a painkiller for dogs with arthritis… pic.twitter.com/5oqTZ8yD61
flashplayer said:
Just give me one freakin day where semis and software rise at the same friggn time.
Got a Natty! said:
I am waiting until POWL gets to $180 and below.